Roche Holding AG (OTCMKTS:RHHBY) Short Interest Update

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 3,665,700 shares, a decline of 68.8% from the February 28th total of 11,741,100 shares. Based on an average daily trading volume, of 5,260,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.1% of the company's stock are sold short.

Institutional Investors Weigh In On Roche

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Minot DeBlois Advisors LLC acquired a new stake in Roche during the fourth quarter valued at $752,000. Hancock Whitney Corp boosted its stake in shares of Roche by 6.8% during the 4th quarter. Hancock Whitney Corp now owns 23,516 shares of the company's stock worth $820,000 after acquiring an additional 1,496 shares in the last quarter. HighPoint Advisor Group LLC grew its position in shares of Roche by 2.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock valued at $387,000 after acquiring an additional 304 shares during the period. SVB Wealth LLC purchased a new position in shares of Roche in the 4th quarter valued at about $555,000. Finally, Altrius Capital Management Inc raised its holdings in Roche by 0.3% in the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company's stock worth $6,399,000 after purchasing an additional 603 shares during the period.

Roche Price Performance

Roche stock traded down $0.43 during midday trading on Monday, hitting $41.92. 5,202,103 shares of the company were exchanged, compared to its average volume of 3,280,667. The business has a fifty day simple moving average of $41.17 and a two-hundred day simple moving average of $38.69. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. Roche has a fifty-two week low of $29.20 and a fifty-two week high of $44.31.

Remove Ads

Wall Street Analyst Weigh In

RHHBY has been the subject of several research reports. Sanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research note on Thursday, January 30th. UBS Group upgraded Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, Morgan Stanley assumed coverage on Roche in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy".

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.